Ciltacabtagene autoleucel, an investigational BCMA-directed CAR-T therapy, sustained efficacy and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma.
Recent Content
- Overt forms advisory board to guide ovarian cancer therapy push
- Flare of clonal hematopoiesis, TP53 expansion and prior melphalan drive post-CAR-T myeloid disorders in multiple myeloma
- Enhanced dynamic risk stratification of smoldering multiple myeloma
- Maximizing RRMM strategy time at doctor appointments
- Don’t underestimate organization’s importance in RRMM care
- Embrace the toughest RRMM conversations ASAP
- A lay of the land in evolving RRMM treatment options
- CD70/CD27 signaling promotes the pathogenesis of multiple myeloma and represents a promising therapeutic target
- New registry aims to support research for pediatric acute myeloid leukemia
- Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)—real world experience from the US multiple myeloma immunotherapy consortium